Inalgex

Quick links to important sections

Inalgex

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Inalgex

What is Inalgex?

Inalgex is a pharmacological treatment classified as a non-steroidal anti-inflammatory drug (NSAID). It is primarily utilized for its analgesic (pain-relieving) and anti-inflammatory properties, making it a common therapeutic option for managing various types of acute and chronic pain.

Composition and Mechanism of Action

The active component of Inalgex works by inhibiting specific enzymes known as cyclooxygenases (COX-1 and COX-2). These enzymes play a critical role in the production of prostaglandins, which are lipid compounds in the body that signal pain and promote inflammation at the site of injury or tissue damage. By reducing the synthesis of these prostaglandins, Inalgex helps to decrease swelling and alleviate the sensation of pain.

Primary Uses

Inalgex is typically indicated for the management of conditions characterized by inflammation and discomfort. These may include:

  • Musculoskeletal pain: Such as discomfort arising from strains, sprains, or back pain.
  • Joint conditions: Including various forms of arthritis that cause persistent inflammation and stiffness.
  • Post-operative recovery: To manage localized pain following surgical procedures.
  • Menstrual discomfort: To alleviate primary dysmenorrhea symptoms.

Therapeutic Role

As a systemic treatment, Inalgex aims to improve a patient's quality of life by enhancing mobility and reducing the physical limitations often caused by inflammatory pain. While it addresses the symptoms of inflammation, it is often used as part of a broader therapeutic strategy tailored to the underlying cause of the patient's condition.

What side effects are possible with Inalgex?

Possible Side Effects and Safety Information

The safety profile of Inalgex (Etofenamate topical) is primarily defined by reactions occurring at the application site, with the potential for systemic effects being significantly lower than with oral Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).


Adverse Reaction Scope

Category Description based on Regulatory Documents
Key Adverse Reactions Primarily localized skin reactions (dermatological) such as redness, itching, burning, and rash.
Frequency Classification Localized skin reactions are the most frequent in clinical use. Contact dermatitis is classified as rare in some official documents, and other severe systemic reactions are generally classified as not known (cannot be estimated from available data) [Source: HPRA SmPC].
System-Organ Classes The primary class affected is Skin and Subcutaneous Tissue Disorders. Rare systemic effects may involve Immune System (allergic reactions) or Gastrointestinal disorders [Source: Patsnap Synapse].

Serious Reactions and Safety Constraints

While highly uncommon, serious adverse reactions documented for the NSAID class include severe allergic reactions (e.g., anaphylactic-like symptoms) and severe forms of dermatitis (blistering). These potential reactions are noted in regulatory information [Source: Patsnap Synapse].

Regarding specific populations, the product is not recommended for use during pregnancy, lactation, and in children/infants as its safety in these groups has not been established in regulatory documentation. Use is restricted to intact skin and should be avoided in patients known to be hypersensitive to Etofenamate or other NSAIDs [Source: HPRA SmPC].

Local skin reactions are generally expected to subside once treatment is discontinued, and systemic side effects are typically only associated with prolonged use over large surface areas.

Overdose and Emergency Response

The official regulatory profile for Inalgex, a topical Nonsteroidal Anti-Inflammatory Drug (NSAID), addresses overdose based on the route of exposure. Regulatory documents state that overdosage resulting from the product's intended use—application to the skin—is not considered a practical possibility. The topical route of administration leads to minimal systemic absorption, making severe or life-threatening systemic outcomes unlikely from simple overuse.

However, the regulatory labeling mandates strict emergency actions in the event of accidental or deliberate ingestion of the topical product. Swallowing the gel or solution introduces the potential for systemic toxicity associated with the active ingredient, an event classified as severe. The official guidance requires that the patient must seek medical advice immediately and immediately go to a hospital.

This mandatory hospitalization is required for professional assessment, observation, and the implementation of adequate therapeutic measures by qualified personnel. The regulatory profile confirms that the overdose risk is constrained to the oral route of exposure, which is the only circumstance requiring urgent intervention. There are no specific overdose manifestations documented for the topical application route, and the official prescribing information does not list a specific antidote for the management of the resulting systemic toxicity.

Therapeutic Uses of Inalgex

What Inalgex Treats: Main Uses and Benefits

Inalgex is generally considered relevant for easing symptoms related to physical discomfort and systemic imbalance, particularly when short-term symptomatic assistance is needed. Its use is typically centered on symptomatic management to help ease the overall symptom load during acute episodes.


Managing Acute Symptomatic Discomfort

Inalgex is applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort. It helps address symptom clusters that may become intense or disruptive and is commonly used when short-term symptomatic assistance is appropriate to support patients during episodes of heightened discomfort. The medication addresses symptoms associated with acute or episodic changes to provide targeted support.

“Inalgex assists with maintaining functional stability when symptoms interfere with routine activities.”


Support for Episodic and Functional Symptoms

This medicine is commonly considered relevant in clinical settings that involve acute or unstable symptom patterns, such as those seen in conditions characterized by periods of heightened symptoms or those involving episodic or fluctuating manifestations. The medication may assist with managing symptoms that create noticeable physiological strain and interfere with daily functioning.


Quick Fact: Symptomatic Assistance Inalgex is applied in scenarios where additional management of discomfort is required to assist with maintaining functional stability.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

This information is derived from official regulatory documentation for the drug class of Inalgex (Nonsteroidal Anti-Inflammatory Drugs, or NSAIDs) and outlines specific eligibility rules and constraints.

Contraindicated Populations

The medicine is absolutely contraindicated for patients with a known hypersensitivity or allergic reaction to Inalgex, aspirin, or other NSAIDs (e.g., asthma, hives). It must not be used by patients undergoing Coronary Artery Bypass Graft (CABG) surgery.

Condition-Based and Age Restrictions

Area Official Eligibility Status
Late Pregnancy Contraindicated from 30 weeks gestation; use is advised against from 20 weeks onwards.
Severe Organ Impairment Contraindicated in advanced renal disease and severe, uncontrolled heart failure; use requires caution and monitoring in patients with hepatic impairment.
Age Limits Pediatric use is often not established below specified age cutoffs. Older adults require special monitoring due to higher risk of serious adverse events.
Gastrointestinal History Use is restricted in patients with a history of GI bleeding, ulceration, or perforation due to increased risk.

Eligibility is strictly defined by these governmental regulatory classifications, which mandate exclusion or limited use based on a patient’s prior history and clinical status.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory assessment of Inalgex (Topical Etofenamate) indicates a low risk for systemic drug-drug interactions. Due to the product's minimal systemic absorption following cutaneous application, systemic pharmacokinetic or pharmacodynamic interactions with orally administered medicines are generally declared as 'None known' in regulatory documents.

Interaction Restrictions and Classifications

Classification Official Regulatory Statement
Systemic Interaction Risk Minimal; official statement is 'None known' for drug-drug interactions.
Contraindicated Combination Co-administration with any other topical preparation when applied simultaneously to the same area of skin.
Administration Restriction Must not be used simultaneously with other topical agents at the same site.
Product-Substance Restriction Formulations containing alcohol must not be applied to broken skin (due to excipient content).

Population-Specific Notes

The label addresses a common NSAID concern by noting that patients undergoing anti-coagulant therapy do not require a change in the recommended dosage of the topical product. This reflects the product's low systemic exposure, which minimizes the clinical relevance of typically significant drug interactions in specialized populations. The profile is primarily defined by local administration constraints rather than systemic interaction risk.

Mechanism of Action

Blocking the Synthesis of Pro-inflammatory Mediators

The drug's mechanism is centered on the reversible inhibition of Cyclooxygenase (COX) enzymes, particularly the COX-2 isoform, which acts as a primary biological target. This molecular interaction prevents the conversion of Arachidonic Acid and restricts the local production of Prostaglandins, which are chemical signals that mediate the inflammatory response. This mechanistic domain initiates the reduction of chemical signals involved in inflammatory pathways.

Modulating Peripheral Nociceptive Signaling

By reducing the local concentration of Prostaglandin E2 (PGE2), the mechanism acts to attenuate peripheral nociceptive signaling. PGE2 typically sensitizes nociceptors (sensory nerve endings); therefore, its absence contributes to reduced sensitization of the nerve endings, increasing the activation threshold of nociceptors. This cascade leads to a change in physiological dynamics that limits the generation and amplification of afferent signals from nociceptors.

Mechanistic Constraint of Localized Action

The drug engages a mechanism highly dependent on transdermal permeation, meaning its efficacy is strictly tied to achieving sufficient local tissue concentration. This functional constraint limits the physiological effect to the application area, supporting localized modulation of the inflammatory cascade in peripheral tissues rather than influencing systemic regulatory processes.

Dosage and Administration Information

How to use Inalgex

Inalgex (etofenamate) is a non-steroidal anti-inflammatory drug (NSAID) available as a gel, intended for cutaneous application only. The instructions for use are established for this medication.

Administration and Dosage

Dosage Form Standard Dosing (Adults, including the elderly) Maximum Frequency
5% w/w Gel Apply a 5–10 cm strip of gel Up to 4 times daily
10% w/w Gel Apply a 2.5–5 cm strip of gel Up to 4 times daily

The gel should be applied to the skin over the affected area and rubbed in gently to facilitate absorption. Hands must be thoroughly washed after application, unless the hands are the specific site being treated.

Treatment Duration and Age Rules

Specific limits are set regarding the treatment duration:

  • Soft Tissue Injuries: Treatment should be reviewed after 14 days and should not generally exceed 6 weeks.
  • Chronic Rheumatic Disorders (e.g., Osteoarthritis): Therapy should be reviewed after 4 weeks.

The use of Inalgex gel is not recommended in children or infants due to a lack of specific studies in the pediatric population. No routine change to the dosage is indicated for patients with renal or hepatic impairment.

Procedural Constraints

Inalgex gel must be applied only to unbroken skin, and contact with eyes or mucous membranes must be avoided. The application site should not be covered with occlusive dressings (tight bandages). These constraints characterize the procedure for topical administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Inalgex

1. Research Evidence for Acute Soft Tissue Injuries

This section summarizes the structure of the clinical trials and systematic reviews that have investigated the use of this medicine for acute conditions, such as recent sprains, strains, and contusions. The research examined outcomes related to acute or disruptive episodes.

Studies conducted during periods of increased symptom activity primarily used short-term, controlled trials. These trials observed adult populations presenting with common localized injuries that occurred within a defined timeframe. The research examined outcomes related to physical discomfort and how these outcomes evolved over the study period, typically lasting less than two weeks.

Studies report how symptoms evolved in the observed populations, as measured by outcomes related to physical discomfort. Data show patterns related to the monitored outcomes when compared to measurements in the placebo control groups. Research examined measured changes and how they related to those observed with other similar topical medicines in active comparator trials.

2. Research Evidence for Localized Rheumatic and Degenerative Pain

This section details the nature of the research that examined the medicine's role in localized chronic conditions, such as Osteoarthrosis or certain types of Soft Tissue Rheumatism. This research scenario explored conditions marked by functional limitations and where symptoms may vary in intensity.

The research base for these conditions was evaluated in intermediate-term controlled trials, which are supplemented by some observational research. The studies were designed to evaluate the medicine in adult and older adult populations diagnosed with localized joint wear or localized inflammation of soft tissues like tendons. Researchers explored outcomes reflecting daily functioning or activity level in addition to outcomes related to physical discomfort.

Studies monitored patient-reported outcomes over observation periods that typically ranged from one to three months. Findings contribute to the broader evidence landscape by describing group patterns for measured symptomatic changes. Research describes data patterns related to the monitored outcomes when evaluated against active control medicines used in the studies.

Frequently Asked Questions (FAQ)

Common questions about Inalgex (FAQ)

Q: How quickly does Inalgex start working after you take it?

A: Clinical studies summarized in the official product information have noted that the maximum pain reduction may occur after approximately three to four days of consistent application. Because Inalgex is a topical medicine, its efficacy is tied to consistent, localized application as directed in the product instructions.


Q: How long do the effects of Inalgex usually last?

A: The recommended application frequency for Inalgex is up to four times daily. Pharmacokinetic studies show the active ingredient has a relatively short half-life of about 3.3 hours following application to the skin, indicating that its action is primarily focused on the local application area.


Q: Can Inalgex be taken every day, or is it only for occasional use?

A: According to the official product information, Inalgex can be used daily for specific, recommended periods. For soft tissue injuries, the treatment should not generally exceed six weeks, and for chronic rheumatic disorders, therapy should be reviewed after four weeks. The official instructions indicate a maximum frequency of application of up to four times per day within these limits.


Q: Does Inalgex interact with alcohol?

A: Because Inalgex is applied to the skin (topical use), only a minimal amount of the active ingredient enters the bloodstream. Therefore, interactions with orally consumed substances, including alcohol, are generally considered minimal or 'none known' in official regulatory documents.


Q: What common supplements should I check for interactions with Inalgex?

A: Official regulatory texts state that the risk of systemic interactions with orally administered medicines or supplements is considered low. This is due to the drug's very low absorption into the body when applied correctly. No specific supplements are listed as requiring avoidance in the official labeling.


Q: Can Inalgex cause problems if taken with blood pressure medication?

A: The risk of systemic drug-drug interactions, including with blood pressure medication, is generally considered minimal. This is a key safety profile advantage of the topical formulation, as very little of the drug reaches the rest of the body compared to an oral medicine.


Q: Can teenagers use Inalgex for pain?

A: The official product information states that the use of Inalgex gel is not recommended in children or infants. This is due to a lack of safety data in the pediatric population required for regulatory approval.


Q: What is the maximum amount of Inalgex that can be taken in 24 hours?

A: Official instructions specify the maximum recommended frequency of application is up to four times daily. A defined quantity of gel is to be applied per dose, setting the limit for the total application amount per day.


Q: Is Inalgex habit-forming or addictive?

A: Inalgex is classified as a non-steroidal anti-inflammatory drug (NSAID). This class of medication is not generally associated with the potential for physical dependence or addiction.


Q: Is there a risk of withdrawal symptoms if I stop taking Inalgex suddenly?

A: As a topical NSAID, Inalgex is not associated with withdrawal symptoms when treatment is suddenly stopped. Localized skin reactions, if they occur, typically subside after the product application is stopped.


Q: Does Inalgex help with nerve pain?

A: The approved indications for Inalgex are specific to inflammatory disorders of the musculoskeletal system, such as sprains, strains, tendinitis, and rheumatic diseases. Specific neuropathic pain (nerve pain) is not listed as an official therapeutic indication in the regulatory documents.


Q: Is Inalgex only for chronic conditions?

A: No. Official product information indicates that Inalgex is used for both acute conditions, such as recent soft tissue injuries, and localized chronic conditions, like some rheumatic disorders or osteoarthrosis. The recommended duration of use depends on the condition.


Q: Can Inalgex affect my ability to drive or operate machinery?

A: Official product information specifically states that the use of Inalgex is not expected to affect the ability to drive or use heavy machinery.


Q: Is it true that Inalgex can affect my mood?

A: The documented side effects for this topical medicine primarily involve localized skin reactions at the application site. Effects on mood or psychiatric disorders are not typically listed among the common or frequent side effects in the official safety profile.


Q: Why is Inalgex sometimes prescribed for conditions other than pain?

A: Inalgex is an NSAID, which means its main therapeutic function is to relieve discomfort by treating both pain and inflammation. Therefore, it is officially indicated for the management of conditions, such as injuries or rheumatic diseases, that involve both symptoms.


Q: Are there specific foods I should avoid while on Inalgex?

A: Since Inalgex is for topical use and has minimal systemic absorption, interactions with food are not expected. Regulatory documents focus on avoiding simultaneous use of other topical preparations on the same area of skin.


Q: Does Inalgex interact with birth control pills?

A: Due to Inalgex's minimal systemic absorption, the overall risk of the medicine interacting with orally administered medications, including hormonal contraceptives (birth control pills), is generally considered low.


Q: Is it normal for Inalgex to cause temporary skin flushing?

A: The most frequent side effects documented are localized skin reactions at the application site, which include redness, itching, burning, and rash. Persistent or severe skin reactions are reasons to consult a healthcare provider.


Q: Can Inalgex affect my blood sugar levels?

A: Systemic side effects are rare due to the low absorption of the topical gel. Effects on metabolism or blood sugar levels are not listed among the documented common or frequent adverse reactions.


Q: Do you have to take Inalgex with food?

A: No, Inalgex is a gel designed for topical application to the skin and is not swallowed or taken orally with food. The instructions focus only on applying the product to the affected area.


Q: Can I crush or split Inalgex tablets?

A: Inalgex is manufactured as a gel or cutaneous emulsion for application to the skin, not as an oral tablet. Therefore, there are no tablets to crush or split, and the product should be used only in its original gel formulation.


Q: Is Inalgex safe for people with a history of ulcers?

A: The risk of gastrointestinal issues is lower with topical Inalgex than with oral NSAIDs due to low absorption. However, official information advises caution for patients with a history of GI bleeding or ulceration. The decision to use it requires monitoring by a healthcare professional.


Q: Can Inalgex be taken with aspirin?

A: Official regulatory documents state that Inalgex is contraindicated (should not be used) if a person has a known hypersensitivity or allergic reaction to aspirin or other NSAIDs, such as experiencing asthma or hives after use.

How should Inalgex be stored and disposed of?

How to Store and Dispose of Inalgex?

Storage Requirements

All regulatory guidelines mandate that Inalgex (Etofenamate topical product) must be stored out of the sight and reach of children. Although specific temperature ranges are often not detailed in public summaries, the product should be stored in a manner that preserves its original integrity and stability until the expiration date. The medicine must be kept in its original container.

Disposal Instructions

Disposal of unused or expired Inalgex must strictly follow the official instructions provided by regulatory authorities, such as the FDA and EMA. The product must be disposed of according to local requirements.

Disposal Method Regulatory Procedure
Preferred Utilize a drug take-back location or program.
Alternative Mix the product with an unappealing substance, seal it in a container, and place it in household trash.

It is prohibited to dispose of the product by throwing it into wastewater or directly into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Inalgex found in:

A-Z Index: